Ardelyx (ARDX) Competitors $4.49 -0.21 (-4.47%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$4.55 +0.06 (+1.31%) As of 07/11/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARDX vs. PCVX, AKRO, KRYS, CYTK, ZLAB, PTCT, RARE, AAPG, MRUS, and ACLXShould you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Vaxcyte (PCVX), Akero Therapeutics (AKRO), Krystal Biotech (KRYS), Cytokinetics (CYTK), Zai Lab (ZLAB), PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), Ascentage Pharma Group International (AAPG), Merus (MRUS), and Arcellx (ACLX). These companies are all part of the "pharmaceutical products" industry. Ardelyx vs. Its Competitors Vaxcyte Akero Therapeutics Krystal Biotech Cytokinetics Zai Lab PTC Therapeutics Ultragenyx Pharmaceutical Ascentage Pharma Group International Merus Arcellx Vaxcyte (NASDAQ:PCVX) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations. Does the media favor PCVX or ARDX? In the previous week, Ardelyx had 6 more articles in the media than Vaxcyte. MarketBeat recorded 9 mentions for Ardelyx and 3 mentions for Vaxcyte. Vaxcyte's average media sentiment score of 1.68 beat Ardelyx's score of 0.75 indicating that Vaxcyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ardelyx 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Do institutionals & insiders believe in PCVX or ARDX? 96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 3.1% of Vaxcyte shares are held by insiders. Comparatively, 4.8% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts recommend PCVX or ARDX? Vaxcyte presently has a consensus target price of $136.50, indicating a potential upside of 279.91%. Ardelyx has a consensus target price of $10.89, indicating a potential upside of 142.51%. Given Vaxcyte's stronger consensus rating and higher possible upside, research analysts clearly believe Vaxcyte is more favorable than Ardelyx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Ardelyx 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk and volatility, PCVX or ARDX? Vaxcyte has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Which has better valuation & earnings, PCVX or ARDX? Ardelyx has higher revenue and earnings than Vaxcyte. Ardelyx is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$463.93M-$3.99-9.01Ardelyx$333.61M3.22-$39.14M-$0.22-20.41 Is PCVX or ARDX more profitable? Vaxcyte has a net margin of 0.00% compared to Ardelyx's net margin of -14.86%. Vaxcyte's return on equity of -17.12% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -17.12% -16.26% Ardelyx -14.86%-34.45%-13.81% SummaryVaxcyte beats Ardelyx on 9 of the 15 factors compared between the two stocks. Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDX vs. The Competition Export to ExcelMetricArdelyxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.12B$2.45B$5.60B$9.11BDividend YieldN/A1.79%5.24%4.02%P/E Ratio-20.419.4227.9620.25Price / Sales3.22729.02430.5799.61Price / CashN/A165.3637.4658.16Price / Book6.154.608.045.49Net Income-$39.14M$31.26M$3.18B$250.27M7 Day Performance4.54%4.80%3.63%4.75%1 Month Performance20.70%5.42%4.04%7.64%1 Year Performance-23.77%-4.36%29.56%16.34% Ardelyx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDXArdelyx4.1299 of 5 stars$4.49-4.5%$10.89+142.5%-22.9%$1.12B$333.61M-20.4190Analyst RevisionPCVXVaxcyte1.8116 of 5 stars$32.00-3.8%$136.50+326.6%-56.2%$4.13BN/A-8.02160News CoveragePositive NewsAKROAkero Therapeutics3.396 of 5 stars$51.52-0.5%$82.50+60.1%+107.6%$4.11BN/A-26.4230Insider TradeKRYSKrystal Biotech4.6785 of 5 stars$139.74-2.3%$211.13+51.1%-25.3%$4.04B$290.52M33.59210Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionCYTKCytokinetics4.0728 of 5 stars$33.36-3.8%$70.92+112.6%-34.3%$3.98B$19.22M-6.31250ZLABZai Lab3.0601 of 5 stars$35.48-2.5%$54.28+53.0%+83.5%$3.94B$398.99M-14.251,869PTCTPTC Therapeutics4.3442 of 5 stars$47.98-2.2%$65.00+35.5%+46.2%$3.80B$806.78M7.371,410RAREUltragenyx Pharmaceutical3.9571 of 5 stars$39.61-0.8%$87.00+119.6%-32.8%$3.74B$560.23M-6.741,294Trending NewsAnalyst ForecastAAPGAscentage Pharma Group InternationalN/A$42.04-1.9%N/AN/A$3.66B$980.65M0.00600News CoverageGap DownMRUSMerus1.8835 of 5 stars$52.58-2.3%$84.64+61.0%-2.4%$3.64B$36.13M-12.8937News CoverageAnalyst UpgradeInsider TradeACLXArcellx2.5539 of 5 stars$65.55-2.4%$111.23+69.7%+16.4%$3.61B$107.94M-21.9280Positive News Related Companies and Tools Related Companies PCVX Competitors AKRO Competitors KRYS Competitors CYTK Competitors ZLAB Competitors PTCT Competitors RARE Competitors AAPG Competitors MRUS Competitors ACLX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDX) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARDX Stock Alerts